20.03.2023 • News

Albaugh Acquires Corteva’s Glyphosate Business

US agrochemicals company Albaugh has acquired DuPont spinoff Corteva Agriscience’s straight-goods glyphosate business for an undisclosed sum. The deal is for intangible assets only, such as trade names, registrations, regulatory data, formulations, patents and know-how used worldwide, excluding Argentina.

Albaugh said the purchase will expand its coverage of straight glyphosate dimethylammonium (DMA) salt formulations and registrations globally.

“This latest acquisition of Corteva Agriscience’s glyphosate business is a perfect fit for Albaugh,” said Albaugh’s chief marketing officer Jens Thorsen. “This will expand our direct access to glyphosate markets in areas where we have not previously had a strong presence, including such countries as Chile, Uruguay, Ecuador, Colombia, and Bolivia, as well as supplementing our existing glyphosate offerings in the US, Canada and Brazil.”

Albaugh has previously acquired Corteva’s glyphosate business in Europe, although timing of this earlier deal was not disclosed. 

© Shutterstock/Fotokostic
© Shutterstock/Fotokostic

Last December, Albaugh Europe added Spanish crop protection company Industrias Afrasa to its stable. Stephen Karl, president of Albaugh's Europe, Middle East, and Africa Region said at the time that Afrasa‘s business – mainly focused on Mediterranean crops – complemented Albaugh’s portfolio, with the facilities in Spain building upon the capabilities of its Slovenia facilities to support the company’s rapid growth.

Headquartered in Ankeny, Iowa, Albaugh claims to be the world’s largest privately held supplier of crop protection products.

Author: Elaine Burridge, Freelance Journalist

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

29 April 2026 | This webinar explores how chemical industry organizations can design a digital‑ and AI‑ready operating model focused on clarity, usability, and measurable value.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read